This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

infliximab (Remicade®)

Reference No. 1067

Publication date:

Appraisal information

infliximab (Remicade®) 100 mg powder for concentrate for solution for infusion

Company: Merck Sharp & Dohme Ltd
BNF category: Gastro-intestinal system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 11/10/2011

Current Progress

Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, infliximab (Remicade®) cannot be endorsed for use within NHS Wales for the treatment of moderately active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant, or who are intolerant to or have medical contraindications for such therapies.
Statement of Advice (SOA)